PT3902803T - Inibidores aza-heterobicíclicos de mat2a e métodos de utilização para o tratamento do cancro - Google Patents
Inibidores aza-heterobicíclicos de mat2a e métodos de utilização para o tratamento do cancroInfo
- Publication number
- PT3902803T PT3902803T PT198457962T PT19845796T PT3902803T PT 3902803 T PT3902803 T PT 3902803T PT 198457962 T PT198457962 T PT 198457962T PT 19845796 T PT19845796 T PT 19845796T PT 3902803 T PT3902803 T PT 3902803T
- Authority
- PT
- Portugal
- Prior art keywords
- mat2a
- aza
- cancer
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785519P | 2018-12-27 | 2018-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3902803T true PT3902803T (pt) | 2023-04-28 |
Family
ID=69400625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT198457962T PT3902803T (pt) | 2018-12-27 | 2019-12-27 | Inibidores aza-heterobicíclicos de mat2a e métodos de utilização para o tratamento do cancro |
Country Status (38)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2020123395A1 (en) | 2018-12-10 | 2020-06-18 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2022026892A1 (en) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
| CN115960098B (zh) * | 2020-09-11 | 2026-04-10 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
| US20240124454A1 (en) * | 2020-12-31 | 2024-04-18 | Nanjing Zaiming Pharmaceutical Co., Ltd. | Tricyclic compound and use thereof |
| DE102021102487A1 (de) * | 2021-02-03 | 2022-08-04 | Aixinno Limited | Verfahren zum Handhaben biologischer Zellkulturen |
| WO2022206730A1 (zh) * | 2021-03-29 | 2022-10-06 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| CN117412967A (zh) * | 2021-06-02 | 2024-01-16 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a抑制剂 |
| AR127404A1 (es) | 2021-10-20 | 2024-01-17 | Insilico Medicine Ip Ltd | Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos |
| KR20240148320A (ko) * | 2021-12-17 | 2024-10-11 | 탱고 테라퓨틱스, 인크. | N-(6-아미노-5-메틸피리딘-3-일)-2-(벤조[d]티아졸-5-일)-5-메틸피페리딘-1-일)-2-옥소아세트아마이드의결정질 형태, 약제학적 조성물 및 이의 사용 방법 |
| CN118414338A (zh) * | 2021-12-21 | 2024-07-30 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a的杂环抑制剂 |
| WO2023169554A1 (zh) * | 2022-03-11 | 2023-09-14 | 赛诺哈勃药业（成都）有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
| JP2025521737A (ja) | 2022-06-27 | 2025-07-10 | 石▲薬▼集▲團▼中奇制▲薬▼技▲術▼（石家庄）有限公司 | 三環式化合物およびその使用 |
| CN117430596A (zh) * | 2022-07-13 | 2024-01-23 | 上海海和药物研究开发股份有限公司 | 二并环类mat2a抑制剂及其用途 |
| AU2023361063A1 (en) | 2022-10-13 | 2025-04-17 | Hanmi Pharm. Co., Ltd. | Novel tricyclic derivative compound and uses thereof |
| CN121241050A (zh) * | 2023-03-06 | 2025-12-30 | 甘李药业股份有限公司 | 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途 |
| CN121586715A (zh) * | 2023-06-14 | 2026-02-27 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a杂环抑制剂的盐、晶型及其制备方法 |
| WO2025166215A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025166260A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted tricyclic guanidino compounds as prmt5 inhibitors |
| WO2025166229A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic amidino compounds as prmt5 inhibitors |
| WO2025166274A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic guanidino compounds as prmt5 inhibitors |
| WO2025166257A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| CA2420286A1 (en) | 2000-08-31 | 2002-03-07 | F. Hoffmann-La Roche Ag | 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| CN110015962B (zh) | 2011-01-28 | 2022-03-15 | 肯塔基大学研究基金会 | 茋类似物和治疗癌症的方法 |
| US20160115164A1 (en) | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| JP6832430B2 (ja) * | 2016-08-31 | 2021-02-24 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞代謝過程の阻害剤 |
| UA125970C2 (uk) | 2017-05-22 | 2022-07-20 | Янссен Фармасьютікалз, Інк. | Заміщені похідні індоліну як інгібітори реплікації вірусів денге |
| US11524960B2 (en) | 2018-03-30 | 2022-12-13 | Servier Pharmaceuticals Llc | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer |
| EA202191800A1 (ru) * | 2018-12-27 | 2021-09-13 | Ле Лаборатуар Сервье Сас | Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак |
| SG11202112952SA (en) * | 2019-05-31 | 2021-12-30 | Servier Lab | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
-
2019
- 2019-12-27 LT LTEPPCT/US2019/068652T patent/LT3902803T/lt unknown
- 2019-12-27 MD MDE20211082T patent/MD3902803T2/ro unknown
- 2019-12-27 HR HRP20230161TT patent/HRP20230161T1/hr unknown
- 2019-12-27 AR ARP190103903A patent/AR117544A1/es unknown
- 2019-12-27 GE GEAP201915703A patent/GEP20237519B/en unknown
- 2019-12-27 KR KR1020217023828A patent/KR102823567B1/ko active Active
- 2019-12-27 DK DK19845796.2T patent/DK3902803T3/da active
- 2019-12-27 EA EA202191801A patent/EA202191801A1/ru unknown
- 2019-12-27 RS RS20230240A patent/RS64135B1/sr unknown
- 2019-12-27 SI SI201930515T patent/SI3902803T1/sl unknown
- 2019-12-27 FI FIEP19845796.2T patent/FI3902803T3/fi active
- 2019-12-27 IL IL284326A patent/IL284326B2/en unknown
- 2019-12-27 UA UAA202104321A patent/UA127525C2/uk unknown
- 2019-12-27 PL PL19845796.2T patent/PL3902803T3/pl unknown
- 2019-12-27 GE GEAP202315703A patent/GEAP202315703A/en unknown
- 2019-12-27 PH PH1/2021/551490A patent/PH12021551490A1/en unknown
- 2019-12-27 WO PCT/US2019/068652 patent/WO2020139991A1/en not_active Ceased
- 2019-12-27 PE PE2021001086A patent/PE20212090A1/es unknown
- 2019-12-27 MA MA54608A patent/MA54608B1/fr unknown
- 2019-12-27 MY MYPI2021003553A patent/MY206578A/en unknown
- 2019-12-27 US US17/418,442 patent/US12077534B2/en active Active
- 2019-12-27 HU HUE19845796A patent/HUE061834T2/hu unknown
- 2019-12-27 PT PT198457962T patent/PT3902803T/pt unknown
- 2019-12-27 JP JP2021538127A patent/JP7418441B2/ja active Active
- 2019-12-27 ES ES19845796T patent/ES2942310T3/es active Active
- 2019-12-27 EP EP19845796.2A patent/EP3902803B1/en active Active
- 2019-12-27 MX MX2021007829A patent/MX2021007829A/es unknown
- 2019-12-27 SG SG11202106637SA patent/SG11202106637SA/en unknown
- 2019-12-27 AU AU2019416349A patent/AU2019416349B2/en active Active
- 2019-12-27 CA CA3124952A patent/CA3124952C/en active Active
- 2019-12-27 TW TW108148216A patent/TWI816962B/zh active
- 2019-12-27 KR KR1020257020196A patent/KR20250093588A/ko active Pending
- 2019-12-27 SM SM20230109T patent/SMT202300109T1/it unknown
- 2019-12-27 CN CN201980092742.2A patent/CN113454085B/zh active Active
- 2019-12-27 CR CR20210410A patent/CR20210410A/es unknown
-
2021
- 2021-06-25 CL CL2021001721A patent/CL2021001721A1/es unknown
- 2021-06-25 ZA ZA2021/04423A patent/ZA202104423B/en unknown
- 2021-06-27 SA SA521422405A patent/SA521422405B1/ar unknown
- 2021-06-27 JO JOJO/P/2021/0172A patent/JOP20210172B1/ar active
- 2021-07-27 CO CONC2021/0009879A patent/CO2021009879A2/es unknown
-
2023
- 2023-12-11 JP JP2023208546A patent/JP2024015340A/ja active Pending
-
2024
- 2024-08-05 US US18/794,610 patent/US20250214988A1/en active Pending
-
2025
- 2025-07-04 JP JP2025113748A patent/JP2025133887A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3902803T (pt) | Inibidores aza-heterobicíclicos de mat2a e métodos de utilização para o tratamento do cancro | |
| IL284324A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| HUE066282T2 (hu) | Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra | |
| IL272948A (en) | ENPP1 inhibitors and their use for cancer treatment | |
| IL272470A (en) | Methods and materials for assessing and treating cancer | |
| IL269150A (en) | Compositions and methods for treating cancer | |
| IL283149A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| IL268814A (en) | Compositions and methods for treatment of cancer | |
| IL261721A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| IL270511A (en) | Combination therapies using niraparib and pembrolizumab for treating cancer | |
| IL263224A (en) | Methods and compositions for treating cancers | |
| IL282776A (en) | Plasmid constructs for treating cancer and methods of use | |
| IL268872A (en) | Methods and compositions for treating cancers using antisense | |
| BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
| IL269157A (en) | Compositions and methods for treating cancer | |
| IL288086A (en) | Methods and materials for treating cancer | |
| HUE059990T2 (hu) | 2-Oxo-tiazol-származékok A2A inhibitorként és a rákos megbetegedések kezelésében alkalmazható vegyületekként | |
| IL274198A (en) | Use of Nox inhibitors to treat cancer | |
| PL3773589T3 (pl) | Inhibitor RET do stosowania w leczeniu raka ze zmianą RET | |
| HUE053927T2 (hu) | Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra | |
| DK3293201T3 (da) | Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer | |
| IL282478A (en) | Materials and methods for treating cancer | |
| IL282041A (en) | Egfr inhibitors for treating keratodermas | |
| EP3487492A4 (en) | USE OF ERIBULIN AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies |